Tarsons Products Limited (TARSONS) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Tarsons Products Limited ₹59.22, price ₹329, upside -82.0%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Weakest SetupStrongly overvalued and low quality.
!Fair value ₹59.22 · Strongly overvalued (−82.0%)
!Quality 40/100
!Expensive Growth(revenue 5y +13.1 %/yr)
!Thin margins · 2.5% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers(1/13)
!Narrow moat17/100
!Evidence only low, so the estimate is less certain
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
58‑month range ₹166.46 – ₹867.38 · fair‑value band ₹44.41 – ₹65.70 · the ₹329.40 price screens above the ₹59.22 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow Tarsons Products in your weekly email
Every Wednesday you see whether Tarsons Products is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Tarsons Products Limited manufactures and trades in scientific plastic labware products in India and internationally.
Show more
Tarsons Products Limited manufactures and trades in scientific plastic labware products in India and internationally. The company offers bottles and carboys; boxes and racks; cell cell culture ware, centrifuge ware, clamps and stands, cryoware, desiccator, tubings and connectors, filtration, genomics and PCR consumables, laboratory equipment and utilities, liquid handling consumables and reusables, magnetic stirrer bar, pp storage plates, sampling aids, vials and tubes, and volumetric reusables. It also provides general lab ware products. Its products are used in molecular biology, cell culture, genomics, proteomics, and immunology. Tarsons Products Limited was incorporated in 1983 and is headquartered in Kolkata, India.
Stock analysis
Tarsons Products Limited (TARSONS) currently trades at ₹329.40, while our model-based Fair Value estimate is ₹59.22, 82.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ₹79.92 per share, and 0 of the 14 models we run sit above the ₹329.40 price.
Bear case: the Dividend Discount group reads lowest at ₹22.12, and 14 of the 14 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹44.41 (bear) to ₹65.70 (bull), the price of ₹329.40 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Tarsons Products Limited reported revenue of ₹4.2B in FY2026 versus ₹3.0B in FY2022, a compound +8.9%/yr. Reported net income was ₹143M in FY2026, compounding −38.6%/yr from FY2022.
Key figures
Market cap ₹17.5B (≈ $182M) · P/E ratio 158.4 · P/S ratio 5.37 · EPS (TTM) ₹2.08 · Dividend yield 0.6% · Net margin 3.4% · Return on equity 2.3% · Return on assets (EBIT) 14.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 9% below its 52-week high and 98% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at −82%, TARSONS screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹17.65 to ₹275.67). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹44.41Fair Value ₹59.22Bull ₹65.70
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹1.06 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+7.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.1%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.2%
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−26.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−27.5%
Dividend (yield on the price)0.6%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.40% → 5%
Compare Tarsons Products Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 191 stocks
Beats the industry median on 1/13 measures
Overall it trails its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside−82.0% · Bottom 25%
Profitability
Return on equity (TTM)2.3% · Below median
Return on assets1.2% · Below median
Net margin (TTM)2.5% · Below median
Operating margin (TTM)−0.9% · Bottom 25%
Growth and dividend
Revenue growth20.7% · Top 25%
Dividend yield (TTM)0.6% · Bottom 25%
Balance sheet
Debt / equity0.33× · Highest 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (TTM)158.4× · Priciest 25%
P/B2.76× · Pricier than median
P/S (TTM)3.97× · Pricier than median
EV/EBITDA15.9× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 25
FUTURE (revenue growth)100· sector 36
PAST (return on equity)9· sector 27
HEALTH (low debt)84· sector 96
DIVIDEND (yield)12· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Tarsons Products Limited (TARSONS) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of ₹59.22 versus a price of ₹329.40, about −82% upside (overvalued).
What is the fair value of TARSONS?
Our model-based fair value for Tarsons Products Limited is ₹59.22 (as of Oct 2, 2026), built from audited fundamentals. The current price: ₹329.40.
What is the quality score of TARSONS?
Tarsons Products Limited has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tarsons Products Limited (TARSONS)?
Our model-based price target is the fair value of ₹59.22 (as of Oct 2, 2026) from 14 valuation models. Cautious scenario ₹44.41, optimistic scenario ₹65.70. It is a calculation from audited fundamentals, not an analyst target.
What is the Tarsons Products Limited stock forecast for 2026?
Our models put fair value at ₹59.22, about −82% upside versus a price of ₹329.40 (overvalued). Cautious scenario ₹44.41, optimistic scenario ₹65.70. The calculation is refreshed regularly with new filings.
What is the revenue of Tarsons Products Limited (TARSONS)?
Tarsons Products Limited reported trailing-twelve-month revenue of about ₹4.4B (latest available figure, as of Oct 2, 2026).
Does Tarsons Products Limited pay a dividend?
Tarsons Products Limited currently shows a dividend yield of about 0.61% relative to its recent price (as of Oct 2, 2026).
What is the intrinsic value of Tarsons Products Limited (TARSONS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tarsons Products Limited it is ₹59.22 per share (as of Oct 2, 2026), against a price of ₹329.40. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Tarsons Products Limited stock overvalued or undervalued in 2026?
As of Oct 2, 2026, TARSONS trades above its calculated fair value: price ₹329.40, fair value ₹59.22, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TARSONS?
No. The price is what the market pays today (₹329.40); the fair value is what the company's own numbers justify (₹59.22). For Tarsons Products Limited the two are ₹270.18 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tarsons Products Limited worth?
The market values Tarsons Products Limited at about ₹17.5B (market capitalisation, as of Oct 2, 2026). Per share that is ₹329.40; our models calculate a fair value of ₹59.22 per share.
What do the bullish and bearish scenarios say about TARSONS?
Our models span a range for Tarsons Products Limited: cautious scenario ₹44.41, base ₹59.22, optimistic ₹65.70 per share (as of Oct 2, 2026, price ₹329.40). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of TARSONS?
Tarsons Products Limited trades at a price-to-earnings ratio of 158.4 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹59.22 is built from several models across several years. Other multiples: P/B 2.8, P/S 4.0, EV/EBITDA 15.9.
How solid is the balance sheet of Tarsons Products Limited (TARSONS)?
Balance-sheet figures for Tarsons Products Limited (as of Oct 2, 2026): return on equity 2.3%, debt of 0.33 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is TARSONS from its 52-week high?
Tarsons Products Limited trades at ₹329.40, about 9% below its 52-week high of ₹361.50 and 98% above the low of ₹166.46 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹59.22 is for.
Which stocks are comparable to Tarsons Products Limited?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tarsons Products Limited stock attractive at the current price?
The data as of Oct 2, 2026: price ₹329.40, calculated fair value ₹59.22 (−82%), Quality Score 40/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TARSONS calculated?
We run Tarsons Products Limited through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹59.22, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Tarsons Products Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tarsons Products Limited (TARSONS)?
The closing price on Oct 1, 2026 was ₹329.40. Our model-based fair value is ₹59.22, about −82% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tarsons Products Limited right now?
The price sits above even our optimistic bull case (₹65.70). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Tarsons Products Limited
How large is the market capitalisation of Tarsons Products Limited (TARSONS)?
The market capitalisation of Tarsons Products Limited is ₹17.5B (≈ $182M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tarsons Products Limited (TARSONS)?
The price-to-sales ratio of Tarsons Products Limited is 5.37 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tarsons Products Limited (TARSONS)?
Earnings per share at Tarsons Products Limited are ₹2.08 (price ÷ EPS = P/E 158.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Tarsons Products Limited (TARSONS)?
The dividend yield of Tarsons Products Limited is 0.6% (payout 96.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Tarsons Products Limited (TARSONS)?
The net margin of Tarsons Products Limited is 3.4% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tarsons Products Limited (TARSONS)?
The return on equity (ROE) of Tarsons Products Limited is 2.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tarsons Products Limited (TARSONS)?
On an EBIT basis the return on assets of Tarsons Products Limited is 14.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tarsons Products Limited (TARSONS)?
The operating margin of Tarsons Products Limited is −0.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tarsons Products Limited (TARSONS)?
Revenue at Tarsons Products Limited is growing +20.7% versus a year earlier (3y avg +14.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tarsons Products Limited (TARSONS)?
Earnings per share at Tarsons Products Limited are growing −58.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Tarsons Products Limited (TARSONS) generate?
The free cash flow of Tarsons Products Limited is −₹71.0M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Tarsons Products Limited (TARSONS) carry?
The net debt of Tarsons Products Limited is ₹3.7B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
